In vivo experiments also confirmed that Ber significantly increased CD8+ T cell infiltration in melanoma tumors and inhibited tumor growth (Figure 6), substantiating Ber’s potential as an immunotherapeutic agent in melanoma treatment. The gene discussed is CD8A; the disease is melanoma.